Keiko Nakajima

Keiko Nakajima is an experienced professional in the field of oncology development, currently serving as Executive Director of Global Oncology Development at Daiichi Sankyo, Inc. since April 2020. Prior to this role, Nakajima worked at Bayer from 2001 to 2020, where responsibilities included serving as Indication Lead for Stivarga HCC and Global Development Leader for Rogaratinib. Previous positions at Bayer involved leadership roles in various oncology products, including Nexavar and Darolutamide. Nakajima's medical background includes positions as an Attending Physician at Nagoya University Affiliate - Kakegawa City Hospital and Visiting Physician at the University of North Dakota, alongside clinical residency and fellowship training at Nagoya University and Toyota Memorial Hospital. Educational qualifications include an MD from Nagoya University and a Master’s Degree in Clinical Research, Oncology from the University of Minnesota School of Public Health.